Drugs & Therapy Perspectives

, Volume 6, Issue 10, pp 1–5 | Cite as

Meropenem: a new carbapenem with potential for treating bacterial meningitis

New Drugs and Therapeutic
  • 6 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wiseman LR, Wagstaff AJ, Brogden RN, et al. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995 50(1): 73–101PubMedCrossRefGoogle Scholar
  2. 2.
    British National Formulary No. 29. London: The Pharmaceutical Press. 1995Google Scholar
  3. 3.
    New Ethicals Compendium. Auckland: Adis International Ltd, 1994Google Scholar
  4. 4.
    Treatment of bacterial meningitis relies on early identification and antibacterial therapy. Drug Ther Perspect 1994 Nov 28; 4(11): 8–10CrossRefGoogle Scholar
  5. 5.
    Buckley MM, Brogden RN, Barradell LB, et al. Imipenem/cilastatin: a reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1992; 44(3): 408–44PubMedCrossRefGoogle Scholar
  6. 6.
    Condon RE, Walker AP, Sirinek KR, et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995 Sep; 21: 544–50PubMedCrossRefGoogle Scholar
  7. 7.
    Huizinga WKJ, Warren BL, Baker LW, et al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 179–89PubMedCrossRefGoogle Scholar
  8. 8.
    Meropenem Study Group of Leuven, London and Nijmegen. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995; 36: 185–200CrossRefGoogle Scholar
  9. 9.
    Hamacher J, Vogel F, Lichey J. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients — a comparison of meropenem and imipenem/cilastatin. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 121–33PubMedCrossRefGoogle Scholar
  10. 10.
    Mouton JW, van den Anker. Meropenem clinical pharmacokinetics. Clin Pharmacokinet 1995 Apr; 28(4): 275–86PubMedCrossRefGoogle Scholar
  11. 11.
    Sieger B, Geckler R. A comparison of meropenem and ceftazidime lus tobramycin in the treatment of hospital-acquired lower respiratory tract infections [abstract]. In: 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy 1993: 236Google Scholar
  12. 12.
    Romanelli G, Cravarezza P, Italian Intramuscular Meropenem Study Group. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 109–19PubMedCrossRefGoogle Scholar
  13. 13.
    Norrby SR, Newell PA, Faulkner KL, et al. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 207–23PubMedCrossRefGoogle Scholar
  14. 14.
    Mouton YJ, Beuscart C, Meropenem Study Group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995 Jul; 36 Suppl. A: 145–56PubMedCrossRefGoogle Scholar
  15. 15.
    Choice of antibacterial drugs. Mett lett 1994 Jun 24; 36(925): 53–60Google Scholar

Copyright information

© Adis International Limited 1995

Personalised recommendations